Marlborough

RXi Pharmaceuticals Corp., a clinical-stage biotechnology company based in Marlborough, has been granted a Chinese patent for the composition and methods of use for compounds that may be used to treat dermal scarring, the company announced Monday.

A three-year contract has been ratified by 198 nurses at the Marlborough Hospital, representing the last Massachusetts Nurses Association-represented hospital to settle a contract, the association announced Wednesday.

How do you measure the economic impact of a business? Judges of MassEcon's Team Massachusetts Economic Impact Awards will make that determination after hearing pitches from 21 finalist companies from across the state Wednesday night, a final phase of the annual contest that recognizes companies that are making their mark on the Massachusetts economy.

Marlborough-based Sunovion Pharmaceuticals has extended a drug discovery and development agreement with a New York company.

Marlborough's Ocata Therapeutics has enrolled its first patient for its Phase 2 clinical trial of a treatment for dry age-related macular degeneration (dry AMD), the company announced.

Marlborough-based Sunovion Pharmaceuticals has received federal approval for its drug Aptiom as a monotherapy for the treatment of partial-onset epileptic seizures, the company announced.

A three-year contract has been negotiated for 198 nurses at the Marlborough Hospital, representing the last Massachusetts Nurses Association-represented hospital to settle a contract, the association announced Thursday.

The founder of ReWalk Robotics, whose U.S. headquarters is in Marlborough, will retire in November and not seek re-election to the board of directors, the company announced. Dr. Amit Goffer will step down as president and chief technology officer of the company, which produces exoskeletons to help those with spinal cord injuries walk again. His resignation will take effect Nov. 18. Goffer founded ReWalk in 20001, following an accident that left him a quadriplegic. He pioneered the invention and development of the ReWalk Robotics wearable exoskeleton, enabling individuals with lower-limb paralysis to walk again.

Ocata Therapeutics of Marlborough has been awarded a federal grant to help pay for further preclinical development of a potential treatment for two forms of lupus, representing a new potential product line, the company announced Monday.

It's something we see more and more: companies packing up and moving to Marlborough, or choosing the area as the best place to launch a new venture. Relocating, laying off, hiring and onboarding so many employees are no easy tasks for these firms that now call MetroWest home. But what if you must do all three as part of the same transition?